<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104229</url>
  </required_header>
  <id_info>
    <org_study_id>0</org_study_id>
    <nct_id>NCT05104229</nct_id>
  </id_info>
  <brief_title>SAVES-IBD: Safety &amp; Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery</brief_title>
  <acronym>SAVES-IBD</acronym>
  <official_title>SAVES-IBD: Safety &amp; Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After Major Surgery for Inflammatory Bowel Disease - A Pragmatic Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended&#xD;
      VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. We will perform an&#xD;
      open label trial of aspirin for VTE prophylaxis compared standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with inflammatory bowel disease who undergo abdominopelvic intestinal surgery are at&#xD;
      increased risk for developing venous thromboembolism, in the form of deep vein thrombosis,&#xD;
      pulmonary embolism and mesenteric vein thrombosis for 90-days after surgery. Despite being&#xD;
      high-risk, the standard of care is to provide mechanical and chemoprophylaxis (unfractionated&#xD;
      heparin or low molecular weight heparin) only while they are hospitalized. There exists&#xD;
      randomized data, in patients who have had surgery for abdominopelvic cancer, confirming the&#xD;
      efficacy of extended post-discharge chemoprophylaxis with either unfractionated heparin or&#xD;
      low molecular weight heparin for 28 days after surgery, but no such data exists for IBD.&#xD;
      There has been a resistance to adopting this for IBD patients due to compliance and cost of&#xD;
      the daily injections. However, recently, a large, multicenter, randomized trial in &gt;3000&#xD;
      patients who underwent total hip or total knee replacement found that extended aspirin (81&#xD;
      mg) twice daily post-discharge was both equivalent and non-inferior to prophylaxis using&#xD;
      full-strength anticoagulation with a factor Xa inhibitor. Therefore, we propose a&#xD;
      prospective, multicenter, open label clinical trial to assess the safety and efficacy of&#xD;
      post-operative venous thromboembolism (VTE) prophylaxis with aspirin 81 mg orally twice daily&#xD;
      for 30-days after surgery for IBD compared with controls receiving standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-armed open-labeled clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VTE Rate</measure>
    <time_frame>30-days after discharge from hospital following IBD surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of bleeding requiring transfusion or intervention</measure>
    <time_frame>30-days after discharge from hospital following IBD Surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1890</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard VTE chemoprophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin VTE chemoprophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81Mg Ec Tab</intervention_name>
    <description>Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care VTE prophylaxis</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18yrs&#xD;
&#xD;
          -  Major abdominopelvic surgery with colon or rectal resection&#xD;
&#xD;
          -  Preoperative diagnosis of Crohn's disease, ulcerative colitis, indeterminate colitis&#xD;
&#xD;
          -  Elective surgery&#xD;
&#xD;
          -  candidate for standard of care VTE prophylaxis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 100 yrs&#xD;
&#xD;
          -  aspirin allergy&#xD;
&#xD;
          -  loop ileostomy closure&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  peptic ulcer disease&#xD;
&#xD;
          -  cirrhosis&#xD;
&#xD;
          -  bleeding or clotting disorder&#xD;
&#xD;
          -  thrombocytopenia&#xD;
&#xD;
          -  chronic renal insufficiency or failure&#xD;
&#xD;
          -  severe anemia &lt; 7 preoperatively&#xD;
&#xD;
          -  need for therapeutic anticoagulation or anti-platelet agents post-operatively&#xD;
             including aspirin, warfarin, heparin, clopidogrel, rivaroxaban, others&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan D Holubar, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan D Holubar, MD, MS</last_name>
    <phone>2164447000</phone>
    <email>holubas@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Main Campus</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan D Holubar, MD/MS</last_name>
      <phone>216-444-7000</phone>
      <email>holubas@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Stefan Holubar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>surgery</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

